Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

XBiotech Stands By Advanced Colorectal Cancer Phase III Study

Executive Summary

The Austin, Texas-based biotech XBiotech has stood by its clinical trial strategy in critically-ill colorectal cancer patients, that could lead to the relatively rapid assessment of cancer agents in this group of patients, including the assessment of its lead product, the anti-IL-1 alpha monoclonal antibody, Xilonix.

You may also be interested in...



XBiotech Says CHMP ‘No’ Was A Surprise, Despite The Signs

Where now for XBiotech? The US firm says that despite a big setback for Xilonix in the EU, it will continue to develop the product in oncology.

I-SPY 2 Helping To Normalize Adaptive Trial Designs

Publication in NEJM of results from Phase II of master protocol study of breast cancer combinations also helps build support for Bayesian statistics.

PIPELINE WATCH - Eight Approvals, Seven Filings And Four Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel